Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Herceptin.

H M Shepard1, P Jin, D J Slamon

  • 1Receptor BioLogix Inc., 3350 W. Bayshore Road. Palo Alto, CA 94303, USA. hms@rblx.com

Handbook of Experimental Pharmacology
|December 12, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinicopathologic features and prognosis of retroperitoneal unicentric Castleman disease: report of 38 patients].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2026
Same author

[Reasonable extent of No.12a lymph node dissection in laparoscopic surgery for locally advanced distal gastric cancer].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2026
Same author

Integrated omics-based analysis reveals distinct microbial-metabolite interaction networks in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps in a Chinese population.

Rhinology·2026
Same author

Integrated omics-based analysis reveals distinct microbial-metabolite interaction networks in eosinophilic and non-eosinophilic chronic rhinosinusitis with nasal polyps in a Chinese population.

Rhinology·2026
Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025
Same author

[Patterns of lymph node metastasis and prognosis in locally-advanced gastric cancer after neoadjuvant immunotherapy combined with chemotherapy].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2025
Same journal

Endothelial Cell Phenotypic Plasticity in Atherosclerosis.

Handbook of experimental pharmacology·2026
Same journal

Endothelial Dysfunction and Neurovascular Alterations in Autism Spectrum Disorder.

Handbook of experimental pharmacology·2026
Same journal

Molecular Mechanisms of Endothelial Shear Stress Mechanotransduction in Health and Disease.

Handbook of experimental pharmacology·2026
Same journal

Microvasculature of the Pancreatic Islets of Langerhans in Health and Diabetes.

Handbook of experimental pharmacology·2026
Same journal

Mechanisms of Actions of Physiological, Pharmacological, and Toxicological Dietary Bioactive Inorganic Boron.

Handbook of experimental pharmacology·2026
Same journal

BNCT Plus Luminescence: New Paradigm for Boron-Containing Drug Design.

Handbook of experimental pharmacology·2026
See all related articles

This review details the development of Herceptin, a targeted therapy for HER2-positive breast cancer. It highlights key decisions in creating the first successful tyrosine kinase inhibitor for cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • The human epidermal growth factor receptor-2 (HER2) is a validated target for cancer therapy.
  • Herceptin is a monoclonal antibody approved for HER2-positive breast cancer treatment, used in over 150,000 women.
  • Understanding the developmental history of Herceptin offers insights into targeted drug discovery.

Observation:

  • The specific developmental history, critical decision points, and rationale for pursuing a monoclonal antibody approach for HER2 have not been fully documented.
  • This review aims to elucidate these pivotal events and decisions.
  • The development of Herceptin represents a significant milestone in targeted cancer therapeutics.

Findings:

  • The review details the critical events and decision-making processes that led to the development of Herceptin.

Related Experiment Videos

  • It explains the strategic choices made during the drug discovery and development program.
  • Herceptin emerged as the first therapeutic agent successfully targeting tyrosine kinases in cancer.

    • Implications:

    • Sharing the Herceptin development experience can inform future drug discovery and development processes.
    • The success of Herceptin provides a model for developing targeted therapies against other HER family members.
    • New therapeutic strategies and future directions for targeting the HER family are discussed.